JP2025509446A - 有機化合物 - Google Patents

有機化合物 Download PDF

Info

Publication number
JP2025509446A
JP2025509446A JP2024553877A JP2024553877A JP2025509446A JP 2025509446 A JP2025509446 A JP 2025509446A JP 2024553877 A JP2024553877 A JP 2024553877A JP 2024553877 A JP2024553877 A JP 2024553877A JP 2025509446 A JP2025509446 A JP 2025509446A
Authority
JP
Japan
Prior art keywords
alkyl
compound
inhibitor
checkpoint inhibitor
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509446A5 (cg-RX-API-DMAC10.html
Inventor
ヴォワザン，モード
ゴディング，スティーブン
エル スナイダー，グレッチェン
イー デイビス，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2025509446A publication Critical patent/JP2025509446A/ja
Publication of JP2025509446A5 publication Critical patent/JP2025509446A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024553877A 2022-03-11 2023-03-11 有機化合物 Pending JP2025509446A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263269209P 2022-03-11 2022-03-11
US63/269,209 2022-03-11
US202363479938P 2023-01-13 2023-01-13
US63/479,938 2023-01-13
PCT/US2023/064202 WO2023173131A2 (en) 2022-03-11 2023-03-11 Organic compounds

Publications (2)

Publication Number Publication Date
JP2025509446A true JP2025509446A (ja) 2025-04-11
JP2025509446A5 JP2025509446A5 (cg-RX-API-DMAC10.html) 2026-03-19

Family

ID=87936112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553877A Pending JP2025509446A (ja) 2022-03-11 2023-03-11 有機化合物

Country Status (8)

Country Link
US (1) US20250186446A1 (cg-RX-API-DMAC10.html)
EP (1) EP4489758A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025509446A (cg-RX-API-DMAC10.html)
KR (1) KR20240158980A (cg-RX-API-DMAC10.html)
AU (1) AU2023232171A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243686A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024010993A (cg-RX-API-DMAC10.html)
WO (1) WO2023173131A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2939676A1 (en) * 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
DK2970279T3 (da) * 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11291666B2 (en) * 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
CA3047579A1 (en) * 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
JP7493460B2 (ja) * 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) * 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment

Also Published As

Publication number Publication date
MX2024010993A (es) 2024-09-17
KR20240158980A (ko) 2024-11-05
AU2023232171A1 (en) 2024-08-22
EP4489758A2 (en) 2025-01-15
CA3243686A1 (en) 2023-09-14
US20250186446A1 (en) 2025-06-12
WO2023173131A2 (en) 2023-09-14
WO2023173131A3 (en) 2023-10-19
EP4489758A4 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
US20250186446A1 (en) Organic compounds
JP7856707B2 (ja) 有機化合物
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
KR20220131918A (ko) 다이아실글리세롤 키나제 조절 화합물
JP7631319B2 (ja) 治療方法
JP2023500396A (ja) ツカレソール誘導体及びその使用
JP2021524835A (ja) Ａｘｌキナーゼ阻害剤およびその使用
KR20240058898A (ko) 히스톤 디아세틸라제 6 및 열 충격 단백질 90의 이중 억제제
EP4520399A2 (en) Organic compounds
HK40112650A (en) Organic compounds
CN118922191A (zh) 有机化合物
RU2822394C1 (ru) Способы лечения
HK40066948A (en) Methods of treatment
HK40102238A (en) Therapeutic compositions and methods for treating tumors
HK40082507A (en) Diacylglycerol kinase modulating compounds
HK40082507B (en) Diacylglycerol kinase modulating compounds
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260310